Kornimate/medical-research-clean huggingface dataset:
imipramine on er+ve and triple negative breast cancer

Conditions: Breast Cancer

Summary: comparing changes in biomarkers from a diagnostic core needle biopsy to surgical pathology specimen or repeat core needle biopsy.

this will be a single arm, non-randomized, pre-surgical clinical trial of women with newly diagnosed triple negative breast cancer comparing changes in biomarkers from a diagnostic core needle biopsy to surgical pathology specimen or repeat core needle biopsy.

Eligibility criteria:
inclusion criteria: * participants may be female or male who are 18 years old or older. * ability to consent to treatment - patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines. * previously untreated breast cancer determined by a core needle biopsy showing invasive ductal carcinoma or invasive lobular carcinoma. * a prior, unrelated, breast cancer is allowed. * all breast cancers with possibility for surgical excision will be included. * patient must be able to take oral medications. patients may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study drug. * females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (β-hcg) pregnancy test result within 14 days prior to the first dose of imipramine. * patients must be eligible for surgical resection of their breast cancer or repeat biopsy after completing treatment. * patients must have a complete history and physical examination within 30 days prior to registration. * patients must have a performance status of ecog 0, 1, 2. * tissue block of initial biopsy specimen is available. * patient may not be concurrently enrolled in another investigational drug treatment study. exclusion criteria: * known diagnosis of major depressive disorder, bipolar depression or psychosis * ecog 3 or 4 * age \>= 70 years * renal impairment defined as egfr \<30 * hepatic impairment as judged by clinical investigator or bilirubin \>2 * as judged by the investigator, severe uncontrolled concurrent medical conditions, psychiatric illness or social condition that would limit compliance with study requirements * history of cardiac disease (arrhythmia, conduction abnormality, congenital prolonged qt syndrome, or prolonged qtc rhythm noted during initial ekg \>480 ms) * current use of ssri, snri, mao inhibitor, tramadol or trazadone; or use of these agents within 14 days * inflammatory breast cancer * suicidal ideation or history of suicide attempt * myocardial infarction within 3 months of study initiation. * patients with angle-closure glaucoma * pregnant or breast-feeding women. as there have been no well-controlled studies conducted with pregnant women to determine the effect of imipramine on the fetus. however, there have been clinical reports of congenital malformations associated with the use of the drug.
dialectical behavioral therapy skills for impulsive aggression

Conditions: Impulsive Aggression; ADHD; Executive Dysfunction

Summary: this trial aims to study the efficacy of dbt skills for impulsive aggression and executive dysfunctions in drug naïve children who are presented with impulsive aggression and adhd and attending child and adolescent clinic at alexandria university hospitals using weekly group therapy for 8 month and testing pre and posttreatment biomarkers of aggression.


Eligibility criteria:
inclusion criteria: * patients from 6 to 13-year-old. * patients diagnosed with adhd and presented with impulsive aggression. * commitment to therapy from the child and the parent. * written consent of all the children parents. * male gender. * drug naïve or stopped medications for at least one month. exclusion criteria: * patients younger than 6 years of age as it's the starting age for dbt-c. * patients who dropped from dbt skills group (missing more than 3 consecutive sessions) whether the child or his parent. * patients diagnosed with drug abuse. * patients with severe sensory impairment or intellectual disability. * drug induced aggression as levetiracetam, topiramate and benzodiazepines. * patients diagnosed with autism spectrum disorder or psychotic disorders.

Keywords: dbt aggression adhd biomarkers executive functions
the clinical efficacy of dfpp in patients with aagn

Conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Summary: the clinical efficacy of double filtration plasmapheresis(dfpp) in patients with antineutrophil cytoplasmic autoantibody associated glomerulonephritis(aagn).

this is a single center, prospective, randomized,controlled study to compare the clinical efficacy of double filtration plasmapheresis (dfpp) combined with intravenous cyclophosphamide (iv-ctx) pulse therapy versus iv-ctx pulse therapy in patients with antineutrophil cytoplasmic autoantibody associated glomerulonephritis(aagn).

Eligibility criteria:
inclusion criteria: * a diagnosis of anca associated vasculitis(aav), using criteria adapted from the disease definitions of the chapel hill consensus conference * serum positive anca and the anca level ≥100 relative unit/ml * with renal involvement and serum creatinine≥3 mg/dl * written informed consent had been provided. exclusion criteria: * other secondary vasculitis * anti-glomerular basement membrane(gbm) positive * severe infection; hepatitis b antigenemia, anti- hepatitis c virus * immunodeficiency; or immunoglobulin g(igg)\<2g/l * life threatening * renal biopsy show globally sclerotic glomeruli\>60% and normal glomeruli\<10% * need renal replacement therapy for more than 4w * received large dose of methylprednisolone(mp),ctx,mycophenolate mofetil(mmf), plasmapheresis or intravenous immunoglobulin(ivig) therapy.

Keywords: double filtration plasmapheresis anca-associated vasculitis
docetaxel + doxorubicin as neoadjuvant chemotherapy in patients with breast cancer

Conditions: Ductal Carcinoma

Summary: primary: to determine the pathological remission following the chemotherapy combination docetaxel and doxorubicin in large breast cancer secondary: * clinical response rate * to investigate the safety of docetaxel doxorubicin combination in the treatment for neoadjuvant chemotherapy of breast cancer * type of surgery (radical/conservative)


Eligibility criteria:
inclusion criteria: * histologically verified breast cancer * large (≥ 3 cm) breast cancer * iib-iiia stage * ecog (eastern cooperative oncology group) status: 0-1-2 * adequate bone marrow reserve: (haemoglobin ≥ 12g/l, absolute neutrophil count (anc) ≥ 2.0x 10\^9, platelets ≥100 000) * laboratory results: * bilirubin ≤ upper limit normal (uln) * serum glutamate pyruvate transaminase (sgpt) ≤ 2.5 uln, serum glutamate oxaloacetate transaminase (sgot) ≤ 2.5 uln, * alk.phosph. ≤ 5.0 uln, * creatinin ≤ uln, if borderline calculated at ≤ 60ml/min * normal cardiac function (the result of left ventricular ejection function (lvef) must be above the lower limit of normal for the institution) * negative pregnancy test * hormonal receptor status assessed exclusion criteria: * pregnancy or lactation * sgot and/or sgpt \> 1.5 upper limit normal, associated with alk.phosph \> 2.5 uln * serious medical condition including but not limited to: * uncontrolled hypertension * active ulcus pepticum * non-stable diabetes mellitus * other contraindication of steroid treatment * myocardial infarction within the last 6 months prior study entry * significant neurologic/psychiatric disorders * active infection * peripheral neuropathy grade ≥ 2 * unstable angina * severe arrhythmia * participation in other clinical trial * prior surgery, chemotherapy, hormonotherapy for breast cancer * past or current history of neoplasm other than breast cancer, except for: curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix, other cancer curatively treated and with no evidence of disease for at least 7 years * history of hypersensitivity to the investigational products or to drugs with similar chemical structures * likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol * treatment with any investigational product in the last 1 month before study entry. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Keywords: breast
dexmedetomidine and morphine as adjuvants to us guided erector spinae plane blocks in elective thoracic surgeries

Conditions: Pain, Postoperative; Pain, Acute; Pain, Chronic; Morphine; Dexmedetomidine; Analgesia

Summary: the aim of this study will be to compare the effects of morphine versus dexmedetomidine when used as adjuvants to local anesthetic (ropivacaine) in erector spinae plane block under ultrasound guidance. a group without an adjuvant will also be compared to the groups.

erector spinae plane block (espb) was first introduced in 2016 as a treatment technique for chronic thoracic neuropathic pain, and rapidly became popular in peri-operative medicine due to its relatively simple technique and low complication rate. it has been also used extensively in thoracic surgery. according to a systematic review, espb can be used effectively as part of multimodal analgesia in thoracic surgery since, when used, opioid consumption decreases. the use of adjuvants has been studied to a limited extent in espb. dexmedetomidine and dexamethasone have been tried as adjuvants in espb and it has been shown that dexmedetomidine is more effective in block prolongation and post-operative opioid consumption. according to our knowledge, morphine has not been used yet as an adjuvant for espb. therefore, the investigators will perform a randomized controlled trial in order to compare morphine and dexmedetomidine as adjuvants in espb in elective thoracotomies in terms of intraoperative and post-operative opioid consumption. intraoperative opioid consumption will be guided by vital signs and nociception-level index (nol) and post-operative opioid consumption will be measured by the amount of morphine consumed by the patient during the first 48 hours post-operatively. secondary outcomes will also be recorded.

Eligibility criteria:
inclusion criteria: * patients undergoing elective thoracotomy for any cause (asa i-iii) exclusion criteria: * known allergy to local anesthetic * local inflammation * severe respiratory distress ( breathing dependence on accessory muscles) * severe spinal deformities * severe ipsilateral diaphragmatic paresis * morbid obesity (bmi\>35 kg/m2) * blood coagulation disorder * known contraindication for administration of dexmedetomidine or morphine * severe cardiovascular disease * systematic use of opioids due to chronic pain * renal or hepatic failure * patients who refuse to participate.
thyroid dysfunction induced by anti-pd-1 therapy in patients with advanced carcinoma

Conditions: Carcinoma

Summary: in this study, we monitored patients with advanced malignant tumors who received anti-pd-1 therapy to observe the characteristic of anti-pd-1 therapy-induced thyroid dysfunction and its correlation with prognosis.


Eligibility criteria:
inclusion criteria: * eighteen years or older * confirmed diagnosis of malignancy * received anti-pd-1 therapy exclusion criteria: * thyroid malignancy or history of thyroid malignancy * thyroid dysfunction before anti-pd-1 therapies * previous icis treatment * less than 2 cycles of anti-pd-1 treatment * no thyroid function monitoring during treatment * known pituitary disease * pregnancy.
screening of low responders for aneuploidy to improve reproductive efficiency

Conditions: Infertility

Summary: the purpose of this study is to assess the impact of comprehensive chromosome screening(ccs) on patients with low ovarian reserve in an effort to improve success during in vitro fertilization and decrease the time to successful pregnancy.

patients will undergo a stimulated ivf cycle culminating with an ultrasound guided egg retrieval procedure and either a fresh or frozen embryo transfer as clinically appropriate and without regard to study. all embryology laboratory procedures will be conducted per routine. once the embryo(s) have reached the blastocyst stage of development patients will be randomized into either the study group or the control group. the solaire trial is "blinded" which means neither patients nor the rmanj study doctor/staff will know to which group the embryos were randomized. the study group will have their embryo(s) biopsied for ccs on day 5, if appropriate, for a fresh day 6 embryo transfer. the control group will not have ccs testing performed on their embryo(s) and may proceed with a fresh or frozen embryo transfer as clinically appropriate. the maximum amount of embryos that can be transferred is two per rmanj protocol. all post-transfer care and pregnancy monitoring will be identical and per routine protocol regardless of study participation.

Eligibility criteria:
inclusion criteria: * age of female partner \ 100,000 motile sperm bmi \< 32 exclusion criteria: * diagnosis of endometrial insufficiency use of oocyte donor/gestational carriers use of surgical sperm or dna banking communicating hydosalpinges (hsg) single gene disorders or sex selection participation in another study

Keywords: single embryo transfer double embryo transfer ccs (comprehensive chromosome screening) aneuploidy low responders
intralesional rituximab for the treatment of conjunctival indolent lymphoma

Conditions: Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma

Summary: phase ii, monocentric, open label study to assess safety and activity of intralesional rituximab for the treatment of indolent cd20+ lymphoma of conjunctiva.

preliminary data suggest intralesional rituximab is able to revert resistance to systemic rituximab in patients with cd20+ indolent lymphoma of the conjunctiva, and the addition of autologous serum seems to exhibit a synergistic effect on tumor regression. these two main aspects will be assessed in this trial.

Eligibility criteria:
inclusion criteria: * histological diagnosis of cd20+ b cell lymphoma subtypes: marginal zone lymphoma, grade 1-2 follicular lymphoma, plasmocytic lymphoma, small lymphocyte lymphoma * conjunctival localization alone (1ea stage; mono- or bilateral) * at least one measurable lesion * age \>/= 18 years * ecog-ps \</=3 * hiv 1-2 negativity * at least one previous treatment (antibiotic or rituximab) exclusion criteria: * concomitant conventional (chemo-, radiation, immuno-), experimental (antibiotic) or corticosteroid anticancer therapy * known allergy to rituximab * systemic symptoms * concurrent diagnosis of pemphigus * postsurgical conjunctival scars

Keywords: oal malt conjunctiva indolent cd20+
establishment of functional mri imaging parameters for use in the evaluation of sickle cell disease

Conditions: Sickle Cell Anemia

Summary: patients with sickle cell anemia (sca) are at an increased risk for damage to brain tissue due to their disease. the investigators are interested in how blood flow and cerebral inflammation are different in sca patients and how that affects brain tissue- the investigators will use a relatively new set of dynamic mri techniques to evaluate these parameters. the investigators will image participants with both sca and matched controls with non-invasive mri.

patients with sickle cell anemia (sca) are at increased risk for episodes of stroke, both overt clinically evident and subclinical lesions only seen on imaging, which have associated morbidity and mortality. in addition, sca patients demonstrate relatively poorer cognitive performance compared to their peers without sca that is believed to be related to the episodes of stroke, but may be present even in their absence. this study is designed to explore potential risk factors in patients with sca that will identify predictors of cerebral damage that may also be modifiable. elevated blood flow in cerebral arteries and increased inflammation are believed to be related to both ischemic lesions and cognitive findings but have not yet been clearly proven. we aim to use new mri techniques which target cerebral blood flow and inflammation to identify differences in sca patients and peers and follow this with an initial exploration of the association between these pathologic findings and cognitive deficits. the investigator does not assign specific interventions to the subjects of the study.

Eligibility criteria:
inclusion criteria: * patient with hbss/hbsb0, * age between 18 and 55 years or age/gender/race/education matched peer exclusion criteria: * previous history of a stroke/transient ischemic attack, * neurosurgery, * head trauma, * seizures, * pulmonary embolism, * deep-vein thrombosis, * bleeding/clotting disorders, * current or previous use of anticoagulation medications

Keywords: inflammation blood flow cognition
a real world study of the treatment of gastric adenocarcinoma with huachansu

Conditions: Gastric Adenocarcinoma

Summary: to evaluate the efficacy and safety of huachansu oral preparation in the treatment of inoperable locally advanced or advanced metastatic gastric adenocarcinoma, including gastric esophageal adenocarcinoma.

in this multicenter, controlled, retrospective, real-world study, the original medical records of participants diagnosed with inoperable locally advanced or advanced metastatic gastric adenocarcinoma (including gastric esophageal junction adenocarcinoma) receive treatment in research centers from january 1, 2014 to december 31, 2019 were collected. to evaluate the efficacy and safety of oral huachansu in the systematic treatment of locally advanced or advanced metastatic gastric adenocarcinoma.

Eligibility criteria:
inclusion criteria: only patients who meet all the following criteria are included in the study: 1. diagnosed with gastric adenocarcinoma (including gastric esophageal junction adenocarcinoma) by histopathology or cytology at the enrolled centers from january 1, 2014 to december 31, 2019. 2. stage of disease (clinical or pathological stage) is locally advanced or advanced (stage iiib-iv) . 3. the doctor judged that the tumor tissue was unresectable. 4. at least two medical records. 5. at least one huachansu oral preparation (tablet, capsule) was used during treatment (observation group only) . exclusion criteria: patients who meet any of the following criteria are not allowed to enter the test: 1. lack of clinical data related to important research indicators (survival). 2. refusal to cooperate with follow-up.
calibration and validation of the masimo temperature device in febrile patients

Conditions: Fever

Summary: the goal of this clinical trial is to test the performance of the masimo noninvasive temperature device in patients with fever. the main question it aims to answer is whether the masimo temperature device is comparable to standard methods of taking temperature such as inserting a probe under the tongue or using a forehead thermometer. participants will be asked to sit still while rounds of measurements are taken using the masimo temperature device and the reference temperature device. researchers will compare the measurements taken with the masimo device with the measurements taken with the reference device.

individual sites are only representative of a subset of the overall population, per iso 80601-2-56:2017(medical electrical equipment - part 2-56: particular requirements for basic safety and essential performance of clinical thermometers for body temperature measurement), and therefore clinical bias and limits of agreement should not be evaluated for the subsets. publication of results should include repeatability from individual sites and the combined clinical bias and limits of agreement (nct05787782, nct05674344, and nct05779397)

Eligibility criteria:
inclusion criteria: * patients age ≥ 1year old * febrile at time of enrollment: ≥ 99.5of/37.5oc for patients ages 1-5 years; ≥ 100.4of/38oc for patients older than 5 years old. * english- or spanish-speaking patient or parent/lar exclusion criteria: * patients deemed not suitable for the study at the discretion of the investigator * patients who are rated as a 1 or 2 emergency severity index
trial of bms-690514 in non-small cell lung cancer subjects who have been treated with gefitinib or erlotinib and are genotypically egfr mutation positive or who have had a prior response

Conditions: Non-Small-Cell Lung Carcinoma

Summary: the purpose of this study is to observe an improvement in overall response rate in nsclc subjects who have been treated with gefitinib or erlotinib and are genotypically egfr mutation positive or who have had a prior a response.


Eligibility criteria:
inclusion criteria: * recurrent, metastatic or progressive nsclc without any indication of radiotherapy. subjects must have: * pathologically confirmed nsclc * previously received treatment with single agent gefitinib or erlotinib and completed treatment at least 2 weeks prior to study entry * any one of the following: * a tumor that harbors an egfr mutation * objective clinical benefit from treatment with gefitinib or erlotinib as defined by either documented and confirmed partial or complete response (recist or who), or significant and durable (≥ 6 months) clinical benefit (stable disease as defined by recist or who) progression of nsclc while on continuous treatment with gefitinib or erlotinib as noted by ct/mri increase in disease after having a confirmed partial or complete response or evidence of ≥ 6 months of sd within 3 months of study enrollment exclusion criteria: * symptomatic brain metastasis * history of tia, cva, or thrombotic/thromboembolic event (within last 6 months) * history of hemoptysis greater than 10 ml/day within last 30 days * uncontrolled or significant cardiovascular disease * history of uncontrolled diarrhea, crohn's disease or ulcerative colitis * inability to swallow tablets, untreated malabsorption or gi surgery that results in inability to absorb protocol therapy * women unwilling to avoid pregnancy or use adequate contraception * history of allergy or adverse drug reaction to gefitinib or erlotinib